Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.

European heart journal

Volumn 33, Issue 14, 2012, Pages 1712-1715

  Landmesser, Ulf ^a   von Eckardstein, Arnold ^a   Kastelein, John ^a   Deanfield, John ^a   Lüscher, Thomas F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVATIVE; THIOL DERIVATIVE; TORCETRAPIB;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; EARLY TERMINATION OF CLINICAL TRIAL; EDITORIAL; HUMAN; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE CORONARY SYNDROME; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; OXAZOLIDINONES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFHYDRYL COMPOUNDS;

EID: 84867162705     PISSN: None     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs182     Document Type: Editorial

References (0)